BiotechTube

Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal Medications

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Burns

Conditions

Burns

Trial Timeline

Sep 1, 2007 → Apr 1, 2014

NCT ID
NCT00634166

About Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal Medications

Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal Medications is a approved stage product being developed by Viatris for Burns. The current trial status is terminated. This product is registered under clinical trial identifier NCT00634166. Target conditions include Burns.

What happened to similar drugs?

2 of 5 similar drugs in Burns were approved

Approved (2) Terminated (2) Active (3)
✅Ceftolozane/tazobactamMerckApproved
✅Pathogen-Reduced Plasma + Crystalloid SolutionsCerusApproved
🔄Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)BayerPhase 3
🔄NexoBrid + Gel VehicleMediWoundPhase 3
🔄NexoBridMediWoundPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00634166ApprovedTerminated

Competing Products

12 competing products in Burns

See all competitors
ProductCompanyStageHype Score
R-Pdf/Gbb 0.01% gelJohnson & JohnsonPhase 2
31
Ceftolozane/tazobactamMerckApproved
35
linezolidPfizerPhase 1
29
Somatropin + 0.09% Saline SolutionPfizerPhase 2/3
38
Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)BayerPhase 3
37
cP12United TherapeuticsPhase 2
39
cNP8United TherapeuticsPhase 1
26
Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL ThrombinBaxterPhase 1/2
29
I-020502BaxterPhase 2
32
Pathogen-Reduced Plasma + Crystalloid SolutionsCerusApproved
25
NexoBrid + Gel VehicleMediWoundPhase 3
30
NexoBridMediWoundPhase 3
30